JMP reiterates Celgene at market outperform

Celgene Corp. was reiterated by JMP Securities analyst Charles C. Duncan at market outperform. Celgene's second-quarter earnings met expectations on the top and bottom lines, on a non-GAAP basis. According to the analyst, the real news is the outperformance of Revlimid sales compared to consensus sales expectations. JMP lowered its full-year 2006 revenue estimates to $890 million from $918 million. Shares of the Summit, N.J.-based pharmaceutical company were up 97 cents, or 2.11%, at $46.97 on volume of 4,916,871 shares versus the three-month running average of 3,963,560 shares. (Nasdaq: CELG)

Zimmer Holdings kept at market perform by JMP

JMP Securities analyst Robert C. Faulkner maintained Zimmer Holdings, Inc. at market perform. According to the analyst, Zimmer is attractive for the value buyer who will buy opportunistically over time for a multi-year holding. The company's revenues were $882 million, slightly below JMP's estimate of $887 million. Earnings per share of $0.83 were close to the analyst's forecasted $0.84. Shares of the Warsaw, Ind.-based orthopedics products company were up $2.26, or 3.73%, at $62.86 on volume of 3,580,900 shares versus the three-month running average of 2,493,020 shares. (NYSE: ZIM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.